AgomAb Therapeutics (NASDAQ:AGMB) Upgraded at Zacks Research

Zacks Research upgraded shares of AgomAb Therapeutics (NASDAQ:AGMB) to a hold rating in a research note published on Wednesday,Zacks.com reports.

Several other equities analysts have also commented on AGMB. Leerink Partners assumed coverage on AgomAb Therapeutics in a report on Tuesday. They set an “outperform” rating and a $36.00 target price for the company. Wall Street Zen raised AgomAb Therapeutics to a “hold” rating in a report on Tuesday, February 17th. Morgan Stanley assumed coverage on AgomAb Therapeutics in a research report on Tuesday. They set an “overweight” rating and a $28.00 price objective for the company. Finally, JPMorgan Chase & Co. initiated coverage on AgomAb Therapeutics in a research note on Tuesday. They set an “overweight” rating and a $32.00 price objective for the company. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $32.00.

AgomAb Therapeutics Stock Performance

AGMB opened at $13.62 on Wednesday. AgomAb Therapeutics has a 12-month low of $12.66 and a 12-month high of $17.45.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.